COVALENT-111 Phase II Study Icovamenib in Type 2 Diabetes – 52-Week Results Oct 7, 2025 at 8:30 AM EDT Click here for webcast Supporting Materials COVALENT-111 Phase II Study Icovamenib in Type 2 Diabetes - 52-Week Results Presentation 1.6 MB
